On the basis of two successful phase III studies in China, Fibrogen Inc. looks headed toward a new drug application submission in the country this year for roxadustat (FG-4592), its oral small molecule to treat anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD) and dialysis-dependent CKD (DD-CKD) patients.